PalliaTech’s vertically integrated, “seed-to sale” business model enables the firm’s network of affiliated entities to function at optimal levels of operational efficiency and excellence across all facets of the enterprise, from cultivation to processing to distribution.
PalliaTech’s multi-state presence is among the broadest in the industry. Operations and/or licenses are in place in eleven states representing important East and West coast markets. Entry into additional states is expected soon.
Leveraging its sophisticated cultivation methods and expertise in agronomy, PalliaTech is capable of growing a vast array of high-quality strains of cannabis indoors and outdoors at a lower cost and at higher yields than its competitors.
All plant products are processed in-house into oils for vaping, edibles, tinctures and other products.
Through the deployment of state-of-the-art cultivation and processing techniques — combined with a strong research and development infrastructure – the company has steadily provided patients with a safe, reliable and consistent product within every market it serves.
PalliaTech invests substantially in its research and development capabilities. It capitalizes upon these investments as a market differentiator – and also to ensure that patients receive the best possible product for addressing their medical needs.
Guided by an advisory board of respected medical experts, PalliaTech partners with universities, doctors, scientists and business advisors to advance scientific development – and to devise new extraction and processing techniques with the help of its proprietary, lab-testing technology. This unique lab-testing technology also enables the PalliaTech network to continuously build out its database of various strains and quality of product from various growers.
PalliaTech is intensely proud of its commitment to patients.
Its dispensary network chiefly does business under PalliaTech’s patient-facing Curaleaf™ brand. Curaleaf’s™ dispensaries are staffed by devoted and experienced teams that provide the highest-quality patient care under strict regulatory and safety standards. Team members work closely with patients to ensure they are making the best product choices.
PalliaTech’ s subsidiaries have also initiated a range of doctor and patient education programs through their dispensaries across multiple states.
PalliaTech has rapidly developed an excellent national reputation as reliable partners within the medical cannabis community among patients, business partners and government officials.
Working closely with lawmakers, regulators and other public officials, the company and its affiliates play an active role in shaping and promoting public policies that serve the long-term interests of the medical cannabis industry as a whole. PalliaTech proudly helps to nurture the creation of a medical cannabis sector in the United States that is transparent, responsible and accountable — and that encourages local economic development.
PalliaTech is well-capitalized for growth in existing markets – and poised for new growth. The company deploys its capitalization to expand the business and to continuously build out its research and development capabilities.
The firm’s operating entities have a consistent record of successful entry into fast-growing, new markets – and then rapidly building highly competent management teams in those new territories. These companies are also proficient in filing applications for medical cannabis licenses.
With the company’s controlling shareholder base rooted in the private equity sector, PalliaTech has positioned itself for ongoing expansion by consistently creating value for investors.
CuraleafTM: PalliaTech’s patient-facing brand
PalliaTech subsidiaries manage the Curaleaf™ brand of product and retail dispensaries in multiple states.
Curaleaf™ distributes the highest standards of cannabinoid -based products in respectful and nurturing dispensary settings. Its dispensaries are thoughtfully designed to offer a compassionate, supportive and pressure-free environment for patients, who may be using medical cannabis to treat a range of conditions from multiple sclerosis and cancer, to chronic pain and epilepsy.
In addition to offering counsel in respect to patient eligibility, the Curaleaf™ team provides patients with user-friendly educational resources and guidance for obtaining safe, consistent and effective products that best meet specific medical needs.
Curaleaf™ dispensaries rigorously comply with all legal and regulatory requirements in every state in which it operates.